Systemic Inflammatory Response Syndrome (SIRS)
0
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Shield TherapeuticsMA - Wellesley
1 programIMproved PREdiction of Severe Sepsis in the Emergency DepartmentN/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Thermo Fisher ScientificPreoperative copeptin level
Shield TherapeuticsIMproved PREdiction of Severe Sepsis in the Emergency Department
Clinical Trials (2)
Total enrollment: 959 patients across 2 trials
Prediction of Inflammatory Response and Hypotensive Syndrome After Cardiac Surgery by Preoperative Copeptin Level
Start: Jan 2017Est. completion: Aug 2017200 patients
N/ACompleted
IMproved PREdiction of Severe Sepsis in the Emergency Department
Start: Mar 2011Est. completion: Sep 2015759 patients
N/ACompleted
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.